Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEBULA-1 efimosfermin alfa in compensated cirrhosis due to MASH
2026-525755-82-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis comparing Efimosfermin alfa with Placebo (2 arms). Primary endpoint: Time from randomization to an adjudicated composite liver-related clinical outcome. Planned start Oct 2026; status: authorised.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on 2026-525755-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525755-82-00.